Somani Hospital was established on February 1st, 2007 by Dr. Rajkumari Somani.DIRECTOR: DR. RAJKUMARI SOMANI

Dr. (Mrs.) Rajkumari Somani has completed her graduation and post graduation from Shri Ramchandra Medical College, Chennai (Deemed University). It was her dedication and devotion in the field of Obst. and Gynaecology that she established a fully dedicated and developed 20 beded hospital with all modern and state of the art medical and surgical facilities. She has established full Laparoscopic / Hysteroscopy Gynecology surgery facilities. She regularly doing Colposcopy.

ONGOING TRAIL

Ref: E7080-M091-511: “A Prospective, Multicentre, Post-Marketing Phase IV Study to Assess the safety and Efficacy of Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HCC)” Site: Somani Hospital, Principal Investigator - Dr. Naresh SomaniRef: Protocol: 0063-17 A global, multicenter, three arms, open-label randomized study to evaluate the e?cacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.Protocol Title :‘A Prospective, Randomized, Multicentre, Comparative, open-label, Parallel study to evaluate the E?cacy, Safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC-3255; Cadila Healthcare Ltd) and Reference-Trastuzumab Emtansine (Kadcyla@, a product of Roche) in HER2- Positive Metastatic Breast Cancer PatientsProtocol Title: A randomized, double-blind, placebo-controlled, phase III study evaluating the e?cacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as ?rst line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1).Protocol Title: “A pilot study (Phase II Trial )of Ge?tinib With Pemetrexed as First-Line Therapy in Patients With Advanced Non-squamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations positive patients.” (Investigator Initiative Trial)Protocol Number: WOC/AMS/CT-44/14 “Asurveillance study on the antibiotic susceptibility pattern of bacterial isolates collected from patients at various Indian tertiary care hospitals”

INVESTIGATOR INITIATIVE CLINICAL TRIAL

A pilot study (Phase II Trial) of Cetuximab with Afatinib as First-Line Therapy in patients With Advanced Non-Sequamous Non-Samall-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Multations positive patients. - PI Dr. Naresh SomaniA pilot study (Phase II Trial ) of Gefitinib/Afatinib with pemetrexed as First-Line therapy in Patients with advanced Non-squamous Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr. Naresh SomaniA pilot study (Phase II Trial ) of Nivolumab with Pemetrexed as Palliative Chemotherapy in Patients with advanced Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr. Naresh Somani

COMPLETED TRAIL

Protocol No. CA209-887: Study Title: Clinical Outcomes of CLL and MCL patients treated with Ibrutinib : An observational retrospective medical chart review from India - (Recruitment Ongoing) - Dr. Naresh Somani